Ingrezza: An Effective Treatment for Tardive Dyskinesia Ingrezza (valbenazine) is a highly effective medication that can help people with tardive dyskinesia (TD). TD is a neurological condition characterized by abnormal involuntary movements, often involving the tongue, lips, face, and limbs. In this article, we will provide you with a comprehensive guide on Ingrezza, including its uses, dosage, demographic, side effects, interactions, and generic options. Uses of Ingrezza Ingrezza is a selective VMAT2 inhibitor approved by the FDA in 2017 for the treatment of adults with tardive dyskinesia. The medication works by reducing the amount of dopamine released by nerve cells in the brain, which helps to improve the abnormal involuntary movements. Dosage Ingrezza is an oral medication available as capsules in 40 mg and 80 mg strengths. The recommended starting dose is 40 mg once daily, which can be increased after a week to 80 mg daily based on the patient's response and tolerability. The maximum daily dose of Ingrezza is 80 mg. The medication can be taken with or without food. Demographic Ingrezza is approved for use in adults aged 18 years and older with tardive dyskinesia. Clinical trials have demonstrated that the medication is effective in reducing the abnormal involuntary movements associated with this condition. Side Effects Like any medication, Ingrezza can cause side effects. The most common side effects include drowsiness, dry mouth, constipation, blurred vision, and dizziness. However, these side effects are generally mild and tend to go away with time. Some other side effects that may occur include headache, nausea, anxiety, and insomnia. If any of these side effects persist or worsen, it is important to consult your doctor immediately. Interactions Ingrezza can interact with certain medications, including strong CYP2D6 inhibitors, such as fluoxetine, paroxetine, and quinidine, which can increase the levels of Ingrezza in the body, leading to increased risk of side effects. Ingrezza can also interact with other medications that prolong the QT interval, such as certain antibiotics and antipsychotics. Therefore, it is essential to inform your doctor about all the medications you are taking before starting Ingrezza. Generic Options Ingrezza is a brand-name medication that does not have a generic version available in the market. However, there are other VMAT2 inhibitors available, including Austedo (deutetrabenazine), which is also approved for the treatment of tardive dyskinesia. It is important to remember that different VMAT2 inhibitors may have different dosing schedules, side effects, and interactions. In conclusion, Ingrezza is a valuable medication for the treatment of tardive dyskinesia, a neurological disorder characterized by involuntary movements. The medication is effective, safe, and well-tolerated, with few side effects. By knowing Ingrezza, its uses, dosage, demographic, side effects, interactions, and generic options, you can make an informed decision about your healthcare needs and choose the best treatment option for you.